BioCentury | Oct 1, 2015
Product R&D

Escaping the liver

...GalNAc targeting Unspecified Liver Hepatitis C virus (HCV) infection Phase II Sevion Therapeutics Inc. (OTCQB:SVON) SNS01-T...
BioCentury | Jan 26, 2015
Clinical News

SNS01-T: Additional Phase Ib/IIa data

...dose-escalation, U.S. Phase Ib/IIa trial showed that the maximum tolerated dose (MTD) of twice-weekly IV SNS01-T...
...events reported were fatigue, infusion reaction, nausea, thrombocytopenia and chills, with no treatment-related deaths. Additionally, SNS01-T...
...SNS01-T Business: Cancer Molecular target: Eukaryotic translation initiation factor 5A (eIF5A) Description: Modified formulation of SNS01...
BioCentury | Sep 15, 2014
Clinical News

SNS01-T: Completed Phase Ib/IIa enrollment

...an open-label, dose-escalation, U.S. Phase Ib/IIa trial evaluating 0.0125, 0.05, 0.2 and 0.375 mg/kg IV SNS01-T...
...company said there were 2 dose-limiting toxicities (DLT) in the 8-patient cohort receiving 0.375 mg/kg SNS01-T...
...SNS01-T Business: Cancer Molecular target: Eukaryotic translation initiation factor 5A (eIF5A) Description: Modified formulation of SNS01...
BioCentury | Jul 24, 2014
Cover Story

It is an RNA world

...that disrupt transcription Senesco Technologies Inc. (OTCQB:SNTI) SNS01-T...
...B cell lymphoma Senesco Technologies Inc. (OTCQB:SNTI) SNS01-T...
BioCentury | Jun 2, 2014
Company News

Fabrus, Senesco deal

...developing Senesco's SNS01-T and bringing undisclosed candidates to the clinic in the next two years. SNS01-T...
...chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL). The product is a modified formulation of SNS01...
BioCentury | Jan 20, 2014
Clinical News

SNS01-T: Interim Phase Ib/IIa data

...cohort of an open-label, dose-escalation, U.S. Phase Ib/IIa trial showed that twice-weekly 0.2 mg IV SNS01-T...
...blood and a second patient with DLBCL had evidence of tumor shrinkage in some lesions. SNS01-T...
...SNS01-T Business: Cancer Molecular target: Eukaryotic translation initiation factor 5A (eIF5A) Description: Modified formulation of SNS01...
BioCentury | Dec 9, 2013
Clinical News

SNS01-T: Phase Ib/IIa ongoing

...continuation to the fourth cohort of an open-label, dose-escalation, U.S. Phase Ib/IIa trial of IV SNS01-T...
...and evaluate 0.375 mg/kg SNS01-T. The trial is evaluating 0.0125, 0.05, 0.2 and 0.375 mg/kg SNS01-T...
...SNS01-T Business: Cancer Molecular target: Eukaryotic translation initiation factor 5A (eIF5A) Description: Modified formulation of SNS01...
BioCentury | Jul 1, 2013
Clinical News

SNS01-T: Interim Phase Ib/IIa data

...the second cohort of an open-label, dose-escalation, U.S. Phase Ib/IIa trial showed that 0.05 mg/kg SNS01-T...
...to 1 case of stable disease in a MM patient at weeks 3 and 6. SNS01-T...
...SNS01-T Business: Cancer Molecular target: Eukaryotic translation initiation factor 5A (eIF5A) Description: Modified formulation of SNS01...
BioCentury | Nov 19, 2012
Clinical News

SNS01-T: Phase Ib/IIa amended

...Senesco said it amended an open-label, dose-escalation, U.S. Phase Ib/IIa trial of twice-weekly IV SNS01-T for...
...MCL. The trial is evaluating 0.0125, 0.05, 0.2 and 0.375 mg/kg SNS01-T in 15 patients. SNS01-T...
...SNS01-T Business: Cancer Molecular target: Eukaryotic translation initiation factor 5A (eIF5A) Description: Modified formulation of SNS01...
BioCentury | Sep 24, 2012
Clinical News

SNS01-T: Additional Phase Ib/IIa data

...the first cohort of an open-label, dose-escalation, U.S. Phase Ib/IIa trial showed that 0.0125 mg/kg SNS01-T...
...SNS01-T twice weekly for 6 weeks in about 15 patients with relapsed or refractory MM. SNS01-T...
...SNS01-T Business: Cancer Molecular target: Eukaryotic translation initiation factor 5A (eIF5A) Description: Modified formulation of SNS01...
Items per page:
1 - 10 of 23